On May 19, the World Health Organization (who) announced that Cansino Biologics Inc(688185) biological covid-19 vaccine was authorized by who for emergency use and included in the global emergency use list (Eul). This is the only Chinese covid-19 vaccine with the third generation technical route certified by who Eul, and it is also the most important approval of Cansino Biologics Inc(688185) new vaccine in history.
The emergency use list (Eul) is a mechanism formed by who to evaluate the applicability of new health products in public health emergencies. The goal is to provide drugs, vaccines and diagnostic tools as soon as possible. In order to make medical products effective as soon as possible and reduce the impact of the epidemic, who launched Eul to simplify the approval process on the premise of ensuring safety and effectiveness, so that newly developed products can be put into practical use as soon as possible. Therefore, Eul is the purchasing list of covid-19 vaccines from all countries in the world. People who choose to vaccinate on this list mean that they have obtained a “global pass” and can freely travel to all countries.
According to the official website of who, at present, the World Health Organization has approved the emergency use of 11 covid-19 vaccines. It is China’s first third-generation technology route Cansino Biologics Inc(688185) vaccine and China’s covid-19 vaccine that is included in the global tight use list this time.
In the first half of 2021, Cansino Biologics Inc(688185) biological covid-19 vaccine completed the pre-trial meeting procedures before the submission of the letter of intent and started the rolling data evaluation, becoming the “Chinese candidate” on the emergency use list. Looking back, when covid-19 epidemic broke out, Cansino Biologics Inc(688185) covid-19 vaccine was approved in the same month. The 55 day R & D was approved and the clinical trial was launched first in the world. In May, the results of phase I and phase II clinical trials were first published in the world’s famous medical journal the lancet, and the global multi center phase III clinical trial was launched. In August of the same year, it obtained the authorization of China’s first covid-19 vaccine invention patent. After China was approved for listing in February 2021, the global multicenter phase III clinical data were released in December, which is also the largest covid-19 vaccine clinical trial in China.
During the review, covid-19 virus continued to mutate, involving variant strains such as alpha, beta and Omicron. Compared with other covid-19 vaccines, the situation is more complex and challenging. The test results show that Cansino Biologics Inc(688185) covid-19 vaccine of the third generation technical route still has higher protective effect than covid-19 vaccine of other 2-needle or 3-needle procedures, even in the case of continuous virus mutation.
Obtaining who certification, on the one hand, means that the quality, safety and effectiveness of vaccines have been recognized. On the other hand, it reflects the quality level and comprehensive strength of a country and enterprise’s pharmaceutical vaccine R & D and production. This will help to deal with the current soaring number of covid-19 infections worldwide, insufficient vaccine supply, slow vaccination progress and other problems, and take an important step towards the accessibility and affordability of China’s covid-19 vaccine in developing countries as a global public product.
It is reported that Cansino Biologics Inc(688185) biology has also developed a global innovative covid-19 vaccine for inhalation, which was approved for clinical use in March 2021. By the end of 2021, phase I / II clinical trials have been completed. This is the world’s first inhalable covid-19 vaccine successfully developed by Cansino Biologics Inc(688185) biology, a Chinese innovative vaccine company, also known as aerosol inhalation immunization.
